Amylin (IAPP)
Amylin (Islet Amyloid Polypeptide, IAPP) is a 37-amino-acid pancreatic hormone co-secreted with insulin from beta cells. It regulates gastric emptying, promotes satiety, and suppresses glucagon. It is the parent compound for pramlintide (Symlin) and cagrilintide (in CagriSema).
Amylin (Islet Amyloid Polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It complements insulin's glucose-lowering effects by slowing gastric emptying, promoting satiety through brainstem signaling, and suppressing inappropriate postprandial glucagon secretion.
Overview
Amylin is secreted from pancreatic beta cell dense-core secretory granules in a fixed ratio with insulin (approximately 1:100 amylin:insulin) in response to nutrient stimulation. It was discovered in 1987 by Garth Cooper and colleagues as a component of the amyloid deposits found in the islets of Langerhans in type 2 diabetes patients. While amylin's aggregation into amyloid fibrils is pathological — contributing to beta cell dysfunction and death in type 2 diabetes — the soluble, monomeric form is a physiologically important hormone that fine-tunes postprandial glucose homeostasis.
Amylin acts primarily through the calcitonin receptor (CTR) in complex with receptor activity-modifying proteins (RAMPs), forming functional amylin receptors (AMY1: CTR/RAMP1; AMY2: CTR/RAMP2; AMY3: CTR/RAMP3). These receptors are expressed in the brainstem (area postrema, nucleus of the solitary tract), hypothalamus, kidney, and bone, mediating amylin's diverse physiological effects.
In type 1 diabetes, amylin is absent (along with insulin) due to beta cell destruction. In type 2 diabetes, amylin secretion is initially elevated (accompanying hyperinsulinemia) but progressively declines as beta cells fail. The aggregation of amylin into toxic oligomers and amyloid fibrils is a hallmark of type 2 diabetes pathology.
Mechanism of Action
Amylin exerts its effects through amylin receptors (CTR/RAMP complexes) via Gs-cAMP signaling:
Gastric Emptying: Amylin slows gastric emptying through vagal efferent signaling, reducing the rate of nutrient delivery to the small intestine. This is one of amylin's most potent effects and contributes significantly to postprandial glucose control by preventing rapid glucose absorption. The gastric emptying effect is dose-dependent and complementary to the similar effect of GLP-1, though mediated through distinct receptor pathways. Young AA et al. (1995) — Diabetologia 38, 642-648.
Central Satiety Signaling: Amylin acts on receptors in the area postrema (AP) and nucleus of the solitary tract (NTS) in the brainstem to reduce meal size and promote satiety. The area postrema is a circumventricular organ that lacks a blood-brain barrier, allowing circulating amylin to access central neurons directly. Amylin's satiety effect is distinct from and additive to that of GLP-1, which acts through a different set of brainstem and hypothalamic circuits. Lutz TA (2012) — Physiol. Behav. 106, 563-568.
Glucagon Suppression: Amylin suppresses postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output. This effect is particularly important in type 1 diabetes, where the absence of amylin (and insulin) leads to unrestrained glucagon secretion and postprandial hyperglycemia.
Insulin Co-Secretion: Amylin is co-packaged with insulin in beta cell secretory granules and released in response to the same stimuli (glucose, amino acids, fatty acids). The co-secretion ensures coordinated postprandial metabolic regulation: insulin promotes glucose uptake and storage, while amylin prevents excessive glucose influx through delayed gastric emptying and glucagon suppression.
Bone Effects: Amylin receptors (particularly AMY1 and AMY3) are expressed on osteoclasts, where amylin signaling inhibits bone resorption. This provides a mechanism linking nutrient intake to bone metabolism, similar to the bone effects of the related peptide calcitonin.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Amylin and Appetite Regulation
Amylin is one of the most potent known satiety signals. Its effects on meal size reduction are mediated through the area postrema and are distinct from cholecystokinin (CCK), GLP-1, and leptin signaling. Amylin also interacts with leptin signaling — co-administration of amylin and leptin produces synergistic weight loss in preclinical models, suggesting that amylin may enhance leptin sensitivity. This amylin-leptin interaction has been explored therapeutically but has not yet produced a successful clinical program. Lutz TA (2012) — PMID: 22108506
Amylin Physiology and the Dual Hormone Model
The recognition that postprandial glucose regulation requires both insulin and amylin led to the "dual hormone" model of glucose homeostasis. Insulin promotes glucose disposal and storage, while amylin prevents excessive postprandial glucose excursions through complementary mechanisms (slowed gastric emptying, glucagon suppression, satiety). In type 1 diabetes, replacement of insulin alone without amylin produces suboptimal glucose control with frequent postprandial hyperglycemia, providing the rationale for pramlintide (amylin analog) as adjunct therapy. Hay DL et al. (2015) — Pharmacol. Rev. 67, 564-600.
Amylin Aggregation and Beta Cell Loss in Type 2 Diabetes
Human amylin is one of the most amyloidogenic peptides known. The region spanning residues 20-29 (SNNFGAILSS) is critical for amyloid fibril formation. In type 2 diabetes, chronic beta cell stress leads to overproduction and misfolding of amylin, which forms toxic oligomers and amyloid fibrils within and around islets. These amyloid deposits contribute to beta cell apoptosis, reduced beta cell mass, and progressive insulin deficiency. Notably, rodent amylin (which has proline substitutions at positions 25, 28, and 29) does not form amyloid, which is why rodent models do not naturally develop islet amyloidosis. Westermark P et al. (2011) — Physiol. Rev. 91, 795-826.
Pramlintide (Symlin) — FDA-Approved Amylin Analog
Pramlintide is a synthetic amylin analog with three proline substitutions (Ala25Pro, Ser28Pro, Ser29Pro) that prevent amyloid fibril formation while retaining full biological activity. It was approved by the FDA in 2005 for adjunct therapy in type 1 and type 2 diabetes. Pramlintide improves postprandial glucose control, reduces HbA1c by 0.3-0.5%, reduces insulin requirements, and produces modest weight loss (1-2 kg). Its primary limitation is the need for three-times-daily pre-meal injections due to its short half-life (~48 minutes). Whitehouse F et al. (2002) — Diabetes Care 25, 724-730.
Cagrilintide — Long-Acting Amylin Analog
Cagrilintide (AM833, NN9838) is an acylated amylin analog developed by Novo Nordisk with a half-life of approximately 4 days, enabling once-weekly dosing. As monotherapy, cagrilintide 4.5 mg weekly produced up to 10.8% weight loss over 26 weeks. In combination with semaglutide 2.4 mg (CagriSema), it produced 15.6% weight loss at 32 weeks — exceeding either component alone. The CagriSema combination is in Phase 3 development (REDEFINE program). Lau DCW et al. (2021) — Lancet 398, 2160-2172.
Clinical Research Protocols
As an endogenous hormone, native amylin is not administered therapeutically. Clinical protocols involve its synthetic analogs:
Pramlintide (Symlin) Dosing Protocols:
- Type 1 Diabetes: Start 15 mcg SC immediately before major meals. Titrate by 15 mcg increments to maintenance dose of 30-60 mcg per meal. Reduce pre-meal rapid-acting insulin by 50% at initiation to prevent hypoglycemia.
- Type 2 Diabetes: Start 60 mcg SC immediately before major meals. Increase to 120 mcg after 3-7 days if tolerated. Reduce pre-meal insulin if applicable.
- Critical: Pramlintide and insulin must never be mixed in the same syringe. Separate injection sites required.
CagriSema Dosing Protocol: Cagrilintide 2.4 mg + semaglutide 2.4 mg co-formulated for once-weekly SC injection. Dose escalation over ~16 weeks to target dose.
Amylin Measurement: Fasting and postprandial amylin measured by radioimmunoassay or ELISA. Normal fasting: 5-10 pmol/L. Postprandial peak: 15-25 pmol/L. Absent in type 1 diabetes. Variable in type 2 diabetes (initially elevated, then declining).
Comparison to Related Compounds
| Parameter | Amylin (endogenous) | Pramlintide (Symlin) | Cagrilintide | Calcitonin | CagriSema |
|---|---|---|---|---|---|
| Source/Type | Pancreatic beta cells | Synthetic analog | Acylated analog | Thyroid C-cells | Combination product |
| Half-life | ~13 minutes | ~48 minutes | ~160 hours (~4 days) | ~12 minutes | ~4 days / ~7 days |
| Dosing | Pulsatile (with meals) | 3x daily (pre-meal) | Once weekly | Variable by indication | Once weekly |
| Amyloidogenicity | High (residues 20-29) | None (Pro25,28,29) | Minimal (engineered) | None | N/A |
| Weight loss | N/A (physiological) | 1-2 kg | ~10.8% (26 wk) | None (not primary) | ~15.6% (32 wk) |
| Receptor | AMY1-3 (CTR/RAMP) | AMY1-3 (CTR/RAMP) | AMY1-3 (CTR/RAMP) | CTR (no RAMP) | AMY + GLP-1R |
| FDA Status | Endogenous | Approved (2005) | Phase 3 (in CagriSema) | Approved (osteoporosis) | Phase 3 |
Amylin vs. Pramlintide: Pramlintide retains all of amylin's biological activities while eliminating the amyloidogenic potential through three proline substitutions (Pro25, Pro28, Pro29) in the critical 20-29 region. These prolines disrupt the beta-sheet conformation required for fibril nucleation. Pramlintide's short half-life (~48 minutes vs ~13 minutes for native amylin) represents a modest improvement but still requires pre-meal dosing.
Amylin vs. Cagrilintide: Cagrilintide extends amylin's half-life from minutes to days through fatty acid (C18 diacid) acylation that promotes albumin binding. This transforms a pre-meal injectable into a once-weekly therapy suitable for chronic obesity treatment. Cagrilintide also incorporates structural modifications to prevent amyloid aggregation.
Amylin vs. Calcitonin: Amylin and calcitonin share structural homology and signal through related receptors (both bind CTR, but amylin requires RAMP co-receptors). Calcitonin primarily regulates calcium homeostasis and bone resorption, while amylin primarily regulates glucose homeostasis and appetite. Both inhibit osteoclast-mediated bone resorption.
Ongoing & Future Research
Active areas of amylin research include:
-
CagriSema Phase 3 (REDEFINE Program): NCT05567796 (REDEFINE-1), NCT05394519 (REDEFINE-2), NCT05813925 (REDEFINE-3) — pivotal trials evaluating cagrilintide + semaglutide for obesity, including head-to-head comparison with tirzepatide in REDEFINE-3.
-
Amylin and Neurodegeneration: IAPP aggregation shares mechanistic similarities with amyloid-beta aggregation in Alzheimer's disease. Cross-seeding between IAPP and amyloid-beta has been demonstrated, and epidemiological links between type 2 diabetes and Alzheimer's disease are well-established. Research is investigating whether amylin-based therapies could have neuroprotective effects.
-
Anti-Amyloid Strategies: Small molecules and peptide-based inhibitors targeting the amyloidogenic 20-29 region of IAPP are being developed to prevent islet amyloid formation and preserve beta cell mass in type 2 diabetes. [NCT entries for islet amyloid studies are primarily preclinical]
-
Next-Generation Amylin Analogs: Development of amylin analogs with further extended half-lives, improved receptor selectivity, and oral bioavailability.
-
Amylin in Type 1 Diabetes: Dual hormone replacement (insulin + amylin analog) for type 1 diabetes is being explored with long-acting analogs that could simplify the pramlintide dosing burden.
Safety Profile
As an endogenous hormone, native amylin is safe at physiological concentrations. Its pathological role relates to aggregation: in type 2 diabetes, amylin forms toxic oligomers and amyloid fibrils that damage beta cells, contributing to progressive beta cell failure. Safety considerations for amylin-based therapeutics (pramlintide, cagrilintide) include: nausea and gastrointestinal symptoms from slowed gastric emptying (the most common adverse effect, typically dose-dependent and transient); hypoglycemia risk when used with insulin (pramlintide labeling requires 50% pre-meal insulin dose reduction at initiation); injection site reactions; and theoretical risk of amylin receptor-mediated effects on calcitonin receptor pathways. Pramlintide and cagrilintide are engineered to eliminate amyloidogenic potential, removing the fibril-formation risk of native amylin. [Hay DL et al. (2015) — PMID: 25527831](https://pubmed.ncbi.nlm.nih.gov/25527831/)
Pharmacokinetic Profile
Amylin (IAPP) — Pharmacokinetic Curve
Molecular Structure
- Formula
- C165H261N51O55S2
- CAS
- 122384-88-7
Research Indications
Neuroprotection (Preclinical)
Preclinical studies show pramlintide decreases amyloid-beta plaques in APP mouse models. Mechanism involves modulation of amyloid aggregation. No human trials for this indication.
Diabetes Management (FDA-Approved)
FDA-approved (2005) as Symlin for adjunctive use with mealtime insulin in T1D patients not achieving adequate glycemic control. Reduces HbA1c by 0.5-0.7% via slowing gastric emptying, suppressing postprandial glucagon, and promoting satiety.
FDA-approved as adjunct to preprandial insulin therapy, with or without metformin/sulfonylurea, in T2D patients. Improves postprandial glucose control through multiple complementary mechanisms to insulin.
Weight Management
Promotes clinically meaningful weight loss (vs. weight gain with insulin intensification alone) by enhancing satiety via hypothalamic receptors. Weight reduction occurs alongside HbA1c improvement.
Phase 2 trial in 204 non-insulin-treated obese subjects showed 3.7% weight loss and 3.6 cm waist circumference reduction. Not FDA-approved for this indication.
Research Protocols
oral
[NCT entries for islet amyloid studies are primarily preclinical] - Next-Generation Amylin Analogs: Development of amylin analogs with further extended half-lives, improved receptor selectivity, and oral bioavailability.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Type 1 Diabetes | 15 mcg, 30-60 mcg | Per protocol | — |
| Type 2 Diabetes | 60 mcg, 120 mcg | Per protocol | 3-7 days |
| CagriSema Dosing Protocol | 2.4 mg | Once weekly | 16 weeks |
Interactions
Peptide Interactions
Glucagon Suppression: Amylin suppresses postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output.
As monotherapy, cagrilintide 4.
The gastric emptying effect is dose-dependent and complementary to the similar effect of GLP-1, though mediated through distinct receptor pathways.
In combination with semaglutide 2.
What to Expect
What to Expect
Rapid onset expected; half-life of ~13 minutes (native) indicates fast-acting pharmacokinetics
Increase to 120 mcg after 3-7 days if tolerated.
Dose escalation over ~16 weeks to target dose.
As monotherapy, cagrilintide 4.5 mg weekly produced up to 10.8% weight loss over 26 weeks.
Continued use as directed
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Extensive peer-reviewed research base
Caution
- Short half-life may require frequent dosing
- Evidence primarily from preclinical studies
- Injection site reactions reported
Frequently Asked Questions
References (7)
- [1]
- [3]Westermark, P. et al Islet amyloid polypeptide, islet amyloid, and diabetes mellitus Physiol. Rev. (2011)
- [5]Whitehouse, F. et al A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care (2002)
- [6]Lau DCW et al — Once-weekly cagrilintide for weight management in people with overweight and obesity Lancet (2021)
- [7]
- [2]
- [4]
Anti-Müllerian Hormone (AMH)
Anti-Müllerian Hormone (AMH) is a TGF-β superfamily glycoprotein produced by granulosa cells and Sertoli cells that serves as a gold-standard biomarker for ovarian reserve assessment, PCOS diagnosis, and male reproductive function. Recombinant AMH is under preclinical investigation as a non-hormonal contraceptive.
ANA Gold (Gold Tripeptide-1)
ANA Gold is a colloidal gold-tripeptide-1 conjugate that combines gold nanoparticle anti-inflammatory and antioxidant properties with tripeptide-1's collagen-stimulating activity for luxury anti-aging skincare applications.